Survodutide
MODERATE EVIDENCEAlso known as: BI 456906
Investigational — in clinical trials, not approved
Educational Overview
A dual GLP-1 and glucagon receptor agonist under clinical investigation for metabolic research. Not approved by any regulator.
Research Mechanism
Dual agonism combining GLP-1 satiety signalling with glucagon-receptor effects on energy expenditure, studied in trial settings.
Areas of Study
- Metabolic regulation (clinical trials)
Safety Considerations
Investigational. No approved human indication anywhere. Research-supplied material is not a medicine and is not manufactured to pharmaceutical standards. Research material only.
Frequently Asked Questions
Is this approved for human use?
No. This material is supplied for laboratory research use only by qualified businesses and institutions. It is not a medicine and is not for human or veterinary consumption.
How do I get pricing?
Request a quote and our team will respond with current pricing and available sizes for your account.
Do you provide purity documentation?
Certificates of analysis are available to approved accounts. Contact our team for batch-specific documentation.
References
References pending editorial review
We publish citations only after a qualified reviewer has verified them against the primary literature. We do not list references we have not checked. (1 queued.)
Last reviewed: 2026-07-23 · Status: in_review · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.